Q3 2026 Laurus Labs Ltd Earnings Call Transcript
Key Points
- Laurus Labs Ltd (BOM:540222) reported strong financial performance with revenues for the third quarter at INR1,778 crores, showing a 26% growth.
- Gross margins have expanded to around 60%, and EBITDA margins increased to over 27%, indicating improved operational efficiency.
- The company has made significant investments in CapEx to enhance development and manufacturing infrastructure, including operationalizing antibody drug conjugate and gene therapy labs.
- The generic division reported a 37% growth in revenues for the quarter, driven by higher ARV volumes and strong offtake in recently launched products.
- Laurus Labs Ltd (BOM:540222) continues to see strong interest in its CDMO business, with a 50% growth in cumulative nine-month performance, supported by recurring business from long-term customer relationships.
- The bio division reported muted sales of INR43 crores for Q3, with longer visibility on demand projections still developing.
- The company expects no meaningful revenues from ADCs in the next two years, indicating a delay in realizing returns from this investment.
- Laurus Labs Ltd (BOM:540222) has a net debt of INR2,092 crores, with a debt-to-EBITDA ratio of around 1.2, which may impact financial flexibility.
- The CDMO business experienced lumpiness in revenue, with Q3 being softer due to timing of deliveries, highlighting potential volatility in this segment.
- The company is not expecting any other income in Q4, which may affect profitability compared to the previous year.
Ladies and gentlemen, good day, and welcome to the Laurus Labs 3Q FY26 earnings conference call hosted by DAM Capital Advisors Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Nitin Agarwal from DAM Capital Advisors Limited. Thank you, and over to you.
Thank you so much. Good afternoon, everyone, and a very warm welcome to Laurus Labs Q3 FY26 Earnings Call hosted by DAM Capital Advisors Limited. On the call today, we have represent Laurus Labs management, Dr. Satyanarayana Chava, Founder and CEO; Mr. V.V. Ravi Kumar, Executive Director; Mr. Krishna Chava, ED, Head, CDMO; Mr. Soumya Chava, ED Generics and Commercial; and Mr. Vivek Kumar, AVP, Investor Relations.
Before we proceed, I would like to remind you that some of the statements made during the call today could be forward-looking in nature, and a Safe Harbor statement to this fact has been included in the press release that has been shared on the company's website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
